PROGRESSION FREE SURVIVAL AT 12 MONTHS AFTER FIRST‐LINE THERAPY IS ASSOCIATED WITH FAVOURABLE OUTCOMES AFTER FIRST RELAPSE/PROGRESSION IN PERIPHERAL T‐CELL LYMPHOMA. (12th June 2019) - Shirouchi, Y.